Chagasic Cardiomyopathy in Immigrants from Latin America to Spain by Pérez de Ayala, Ana et al.
LETTERS
Chagasic 
Cardiomyopathy 
in Immigrants from 
Latin America 
to Spain 
To the Editor: An estimated 8 
million persons in 21 countries in the 
Western Hemisphere are infected by 
Trypanosoma cruzi, the cause of Cha-
gas disease. The global infection rate 
is 1.4% (1) and varies by geographic 
area from 0.1% to 45.4% (2). After in-
fection, organ involvement, predomi-
nantly cardiac disease, will develop in 
20%–30% after 10–30 years (3).
Worldwide, Spain is second to 
the United States in having the larg-
est number of immigrants from Latin 
America (4). In 2008, immigrants ac-
counted for 11.3% of the population 
in Spain. A total of 1,607,699 were 
from T. cruzi–endemic areas; of these, 
239,942 are from Bolivia (5), the 
country with the highest prevalence of 
T. cruzi infection (2).
Imported Chagas disease may 
emerge in Europe. Chronic Chagas 
disease was diagnosed in 120 patients 
during 2003–2008 at the Tropical 
Medicine Unit, Ramón y Cajal Hos-
pital, in Madrid, Spain. Of these pa-
tients, 22.5% had cardiac involvement 
and 95.8% were from Bolivia. Similar 
data have been observed in other cities 
in Spain and Europe (6,7).
Successful control programs for 
Chagas disease have been conduct-
ed in Latin America in recent years. 
However, because this disease may 
have a latency period of many years, 
infection in immigrants may vary de-
pending on background prevalence in 
the country of origin.
To calculate Chagas disease prev-
alence in Latin American immigrants, 
we considered different values. The 
number of registered immigrants in 
Spain according to country of origin 
for 2007 (5) and infection prevalence 
rates in blood donors for different 
disease-endemic countries (1993–
2002) (2) were recorded. The lowest 
and highest prevalence rates for each 
country were applied to the number of 
immigrants from that country living in 
Spain. Thus, estimates were obtained 
for the number of potentially infected 
immigrants for each country of origin. 
From these ﬁ   gures, a range for the 
total number of potentially infected 
immigrants was calculated. Taking 
into account that all blood donors, but 
only 80.2% of registered immigrants 
in Spain (5), are adults, we applied 
an age-correction factor of 80.2% to 
these  ﬁ   gures (multiplying 80.2% by 
the total) (Table).
Two possible scenarios were then 
deﬁ  ned to estimate the number of cha-
gasic cardiomyopathies that may arise 
in the immigrant population. For the 
best-case scenario, the lowest calcu-
lated number of potentially infected 
immigrants (29,485) was used with 
the lowest rate of progression to cardi-
ac involvement (20%). For the worst-
case scenario, the highest number of 
infections (98,030) was calculated and 
used with a 30% risk of progression to 
cardiac disease. On the basis of these 
estimates, 5,897–29,409 cases of cha-
gasic cardiomyopathy may be diag-
nosed in the near future in Spain.
Information on the prevalence of 
T.  cruzi infection has changed over 
time, and the immigrant populations 
may not be a representative group 
from disease-endemic areas. Thus, 
extrapolating these ﬁ  gures to the cur-
rent population in Spain may pose 
some problems. However, prevalence 
data in Bolivia (9.9% in 2001) (2), the 
country with the highest rates of in-
fection, are consistent with data from 
Spain (2005–2006), which reported a 
seroprevalence rate of 10.2% in blood 
donors from Bolivia (8).
In recent years, vector control 
programs in Chagas disease–endemic 
countries have inﬂ  uenced  infection 
rates. However, most adult immi-
grants became infected during their 
childhood, particularly in Bolivia, be-
fore any vector control programs were 
started. Thus, estimated infection rates 
in adults should not be greatly biased. 
In a recent study in Spain, the average 
age of patients with Chagas disease 
who came to clinics was 35 years (6), a 
ﬁ  nding similar to that seen at our unit. 
At this age, one might expect infected 
patients to show cardiac involvement 
caused by Chagas disease, as well as 
other manifestations such as mega-
esophagus and megacolon (3).
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Table. Immigrants in Spain from Chagas disease–endemic countries in South America 
potentially infected with Trypanosoma cruzi, 1993–2002* 
Characteristic
No. immigrants, 
2007†
Seroprevalence in 
blood donors, %‡ 
Potential no. 
infected immigrants§
Country 
 Ecuador  420,110 0.1–0.2 420–840
 Colombia  280,705 0.1–1.2 280–3,368
 Bolivia  239,942 9.9–45.4 23,754–108,933 
 Argentina  145,315 4.4–5.5 6,393–7,992
 Peru  120,272 0.1–0.2 120–240
 Brazil  115,390 0.6–0.7 692–807
 Venezuela  57,679 0.6–1.3 346–749
 Paraguay  66,710 2.8–4.7 1,615–3,135
 Chile  45,515 0.4–1.2 182–546
 Uruguay  49,970 0.4–0.6 199–299
Total 1,541,608 36,567–122,232 
No. adults¶  1,236,369 29,485–98,030 
Estimated no. chagasic cardiomyopathies  5,897–29,409 
*Infection determined on the basis of seroprevalence data from blood donors. 
†Data obtained from the Instituto Nacional de Estadística (5).
‡Data obtained from Schmunis and Cruz (2). 
§Calculated by applying seroprevalence data for blood donors in countries endemic for Chagas 
disease to no. immigrants from each of these countries living in Spain. 
¶A correction factor for age was applied (80.2% of immigrants in Spain are adults). LETTERS
Screening for Chagas disease 
should be recommended to all Latin 
American migrants, especially those 
from Bolivia. This screening would 
enable early treatment for persons in 
the chronic asymptomatic phase or 
those with mild cardiac involvement, 
persons for whom treatment has been 
recommended (9).
Current legislation in Spain 
makes screening all at-risk blood 
donors mandatory (10). However, 
screening of pregnant women from 
Chagas disease–endemic countries is 
not compulsory, although 46.8% of 
immigrants in Spain are female and 
birth rates in this group are higher 
than the national average for Spain 
(5). Detection of antibodies to T. cruzi 
during pregnancy would also be a use-
ful public health strategy because it 
would enable early speciﬁ  c treatment 
of affected newborns. Screening of 
blood or organ donors would also be 
necessary in countries where there is 
no transmission by vectors.
T. cruzi infection may become a 
public health problem in countries in 
Europe that receive immigrants from 
disease-endemic areas. Thus, chagasic 
cardiomyopathy may soon have a seri-
ous effect on public health in Spain.
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Lethal Bluetongue 
Virus Serotype 1 
Infection in Llamas
To the Editor: Since 1999, of the 
24 known bluetongue virus (BTV) se-
rotypes, ﬁ  ve (1, 2, 4, 9, and 16) have 
spread extensively throughout por-
tions of the Mediterranean basin. Since 
2006, the range of serotype 8 (BTV-8) 
has extended northward into areas of 
Europe never before affected, causing 
the greatest epizootic of the disease on 
record. In 2008, a severe epizootic of 
serotype 1 (BTV-1) occurred in south-
western France; >3,340 outbreaks oc-
curred in <4 months. We report 2 of 
these outbreaks, which indicate that 
BTV-1 can infect llamas and induce a 
lethal disease.
The  ﬁ   rst outbreak occurred in 
September 2008 on a sheep breed-
ing farm in Crampagna, France. After 
bluetongue disease was suspected on 
the basis of clinical signs, all sheep 
and all 9 healthy llamas on the farm 
were tested for BTV by quantitative 
real-time reverse transcription–PCR 
(qRT-PCR) (Taqvet BTV “All geno-
types,” LSI, Lissieu, France). Of the 
9 llamas, 7 had positive results; cycle 
threshold (Ct) values ranged from 28.1 
to 36.2, indicating that these animals 
were sensitive to BTV infection. Se-
rotype 1 was conﬁ  rmed by a speciﬁ  c 
qRT-PCR. After 6 weeks, all infected 
llamas showed serologic response to 
BTV (ELISA ID Screen; Bluetongue, 
ID-Vet, Montpellier, France), and 1 
llama remained positive by qRT-PCR, 
which suggests that viremia lasted at 
least 42 days in this animal. None of 
the 9 llamas showed clinical signs dur-
ing the outbreak.
 The second outbreak, also dur-
ing September 2008, was identiﬁ  ed 
on a llama breeding farm in Auzat, 
France. Two days before the onset of 
the disease, 1 female had aborted a 10-
month-old fetus; she had no additional 
clinical signs. Of the 20 llamas on the 
farm, clinical signs were observed for 
608  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 4, April 2009